Increasing our understanding of the mechanisms of NK cell activation, including those regulated by different molecular checkpoints and hormone receptors, and the identification of new tumor biomarkers will provide a firm basis for how to optimize NK cell reactivity against cancer. This evidence concerns the gene NR4A1 and cancer.